Compare CNNE & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNNE | AURA |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 609.0M | 713.4M |
| IPO Year | 2017 | 2021 |
| Metric | CNNE | AURA |
|---|---|---|
| Price | $14.83 | $8.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $20.25 | $20.00 |
| AVG Volume (30 Days) | ★ 411.3K | 374.3K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.47% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $499,700,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3.37 | N/A |
| 52 Week Low | $10.46 | $4.73 |
| 52 Week High | $19.88 | $9.54 |
| Indicator | CNNE | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 53.76 | 68.16 |
| Support Level | $14.05 | $6.65 |
| Resistance Level | $15.14 | $9.54 |
| Average True Range (ATR) | 0.42 | 0.33 |
| MACD | -0.03 | 0.10 |
| Stochastic Oscillator | 67.83 | 96.96 |
Cannae Holdings Inc is an investment holding company that acquires and actively manages equity interests in operating businesses across various industries. The Company focuses on long-term ownership and seeks to create value by supporting the growth and operations of its portfolio companies through management expertise and strategic oversight. The Company operates through four reportable segments: Restaurant Group, which includes the operations of O'Charleys and 99 Restaurants; Alight, which represents its ownership interest in a technology-enabled human capital and employee benefits solutions provider; Black Knight Football Club (BKFC), which holds interests in professional football clubs; and JANA, which represents its investment in an investment management firm.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.